HOME >> MEDICINE >> NEWS
Neural transplants provide persistent benefit in patients with Huntington's disease

Neuronal transplantation in Huntington's disease provides a period of improvement and stability of several years, according to an Article published online today (Monday February 27, 2006) by The Lancet Neurology.

Intracerebral cell therapy, which aims to substitute striatal neurons lost to Huntington's disease by striatal neuroblasts and neural precursors obtained from embryos after elective abortion, has proven beneficial in patients with the disease. Theoretical projection models suggest that the clinical effects of grafting will lead to an initial improvement followed by a period of secondary decline due to the ongoing disease process. However, follow-up has not been long enough to assess the duration of clinical benefit of the treatment up to now.

Anne-Catherine Bachoud-Lvi (Henri Mondor Hospital, France) and colleagues have previously shown, in a pilot study, that intracerebral neural grafts lead to motor and cognitive improvement in patients with Huntington's disease 2 years after the procedure. In their current article, they present data for five patients from their pilot study, assessed annually for up to 6 years after neural grafting.

The procedure provided long-term clinical benefits to three patients in parallel with long-lasting focal improvement in brain metabolic activity. Progression of the disease led to heterogeneous secondary clinical alterations and changes of cerebral metabolism.

Whereas neuronal transplantation is not a permanent cure for Huntington's disease, it does provide a period of improvement and stability. Although neuroprotective treatment seems to be unavoidable in the disease, improvement of the surgical procedure and in patient selection could improve the therapeutic value of neuronal transplantation. Bachoud-Lvi concludes: "Neuroprotection could stop the disease, but only a graft can restore lost function."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
26-Feb-2006


Page: 1

Related medicine news :

1. Neural networking nanotubes
2. Neural development protein disproved as marker for schizophrenia
3. Neural cell transplants fight immune attack in mice with multiple sclerosis
4. Thymus transplants gives hope to babies with fatal immune disease
5. Outcomes for patients with hepatitis B who need liver transplants
6. Women given liver transplants outlive male recipients by around 4 years
7. How tumors respond to treatment prior to liver transplants may be useful in selecting recipients
8. National trial gives unprecedented support for steroid withdrawal in kidney transplants
9. Organ transplants just as successful in those with mental retardation
10. Liver transplants can be successful in HIV patients with Hepatitis B
11. Stem cell transplants improve recovery in animal models for stroke, cerebral palsy

Post Your Comments:
(Date:7/31/2014)... Dublin, Ohio (PRWEB) July 31, 2014 ... solutions for health care, announces the release of a “Twelve ... web seminar for hospitals that are evaluating Health Information Service ... 2. Hospitals that utilize MEDITECH and Epic electronic health ... order to exchange transitions of care using the Direct protocol. ...
(Date:7/31/2014)... 2014 A cancer diagnosis is crushing and ... and resume normal lives. This is particularly true of prostate ... one in seven American men but which when detected early, ... rate of nearly 100% and a ten-year survival rate of ... diagnosed with the disease do not die from it. There ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on nine secrets that addicts don’t want others to know. ... an addict from a mile away, and totally understand what’s ... Per Wickstrom . “However, take it from me: spotting ...
(Date:7/31/2014)... July 31, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is looking at 10 tips ... , “Addiction recovery is a lifelong process, and one ... be committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... Oregon (PRWEB) July 31, 2014 ... properties and digestibility, erythritol has long been used ... such as stevia and monk fruit. However consistent, ... In an effort to meet food and beverage ... sourcing, Steviva Ingredients has launched GMO-free ErysweetTM Erythritol. ...
Breaking Medicine News(10 mins):Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 2Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 3Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 4Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Steviva Ingredients Launches Erysweet Erythritol 2
(Date:7/30/2014)... Calif. , July 30, 2014  El Camino ... improve patient care, is utilizing the Leaf Patient Monitoring ... the position and movement of patients susceptible to bed ... a six month-long, 138-patient study of the system, which ... turn protocols. Turning patients regularly is the one of ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... July 30, 2014 Cynosure, Inc. (NASDAQ: ... aesthetic treatments for non-invasive and minimally invasive applications, today announced ... Chief Operating Officer and Chief Financial Officer Timothy W. ... 2014.  Baker, 53, will continue to serve as CFO and ... , who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
Cached News: